HAIFA, Israel, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Senior Scientists at Pluristem will be presenting updated developments relating to the company's proprietary 3D cell expansion technology. These innovations will be implemented in Pluristem's new state-of-the-art manufacturing facility for expansion of placental-derived mesenchymal-like Adherent Stromal Cells (ASCs).
The presentations will take place at Engineering Conferences International's Scale-Up and Manufacturing of Cell-Based Therapies II Conference to be held January 21-23, 2013 at the Hyatt Regency Mission Bay Spa and Marina in San Diego, California.
Ohad Karnieli PhD, MBA and VP of Development at Pluristem will give an oral presentation entitled, "Bioreactors in Cell Therapy, the Advantages of High-Throughput Culturing Technologies and the Downstream Challenges". During this talk, Dr. Karnieli will present Pluristem's new production line and demonstrate how the company has drawn on its vast experience in high-throughput culturing to solve many of the problems related to the mass production of ASCs. Dr. Karnieli's presentation will be made available at the company's website http://www.pluristem.com/index.php?option=com_content&view=article&id=3&Itemid=114 for the next 30 days.Eytan Abraham PhD and Product Innovation Research Manager at Pluristem will give a poster presentation entitled, "From Gene Expression to In Vivo Models - Characterization and Potential Therapeutic Properties of Placenta Derived Mesenchymal-Like Adherent Stromal Cells". In this poster, Dr. Abraham will be addressing the specific changes that occur in gene regulation and protein secretion when ASCs are grown in a 3D culturing phase and the biological changes and therapeutic advantages of implementing this technology in the mass expansion of ASCs use. About Pluristem Therapeutics Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem is focusing on the development of PLX cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts